Previous 10 | Next 10 |
home / stock / fh:cc / fh:cc news
Magdalena Biosciences, a joint venture recently formed by Jaguar Health and Filament Health Corp., is focused on developing novel, natural prescription medicines derived from plants for mental health indications Magdalena launches corporate website SAN FRANCISCO, CA / ACCESSWIRE / ...
FILAMENT HEALTH ANNOUNCES HEALTH CANADA AUTHORIZATION FOR PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR OPIOID USE DISORDER Canada NewsWire Filament-sponsored research will study its botanical psilocybin drug candidate, PEX010 VANCOUVER, BC , Oct. ...
FILAMENT HEALTH CORP. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT UNIT OFFERING LED BY NEGEV CAPITAL Canada NewsWire VANCOUVER, BC , Sept. 29, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE:7QS) (" Filament " or the " Company "), a...
Magdalena Biosciences is focused on developing novel, natural prescription medicines derived from plants for mental health indications Import of coca leaves was authorized by the Peruvian Health Authority SAN FRANCISCO, CA / ACCESSWIRE / September 21, 2023 / Jaguar Health, Inc. (NASD...
FILAMENT HEALTH AND JAGUAR HEALTH JOINT VENTURE MAGDALENA BIOSCIENCES COMPLETES IMPORT OF COCA LEAF FROM PERU Canada NewsWire The import to Filament's Metro Vancouver facility was conducted in collaboration with the Peruvian government and facilitated by Filament Health and Ja...
FILAMENT HEALTH ENTERS LICENSING AGREEMENT WITH RESET PHARMA Canada NewsWire Reset Pharma has licensed Filament's botanical psilocybin drug candidate for a phase 2 clinical trial studying demoralization syndrome VANCOUVER, BC , Aug. 31, 2023 /CNW/ - F...
FILAMENT HEALTH AND NASDAQ-LISTED SPAC JUPITER ACQUISITION CORP. ANNOUNCE FILING OF SEC REGISTRATION STATEMENT Canada NewsWire VANCOUVER, BC , Aug. 15, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a...
FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND REFILES Q1 2023 INTERIM FINANCIAL STATEMENTS AND MD&A FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND REFILES Q1 2023 INTERIM FINANCIAL STATEMENTS AND MD&A Canada NewsWire VANCO...
FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF TWO CLINICAL TRIALS STUDYING ITS BOTANICAL PSILOCYBIN DRUG CANDIDATE PEX010 Canada NewsWire The University of Washington and the University of California, Los Angeles have been approved to study PEX010 in clinical trials for me...
VANCOUVER, BC / ACCESSWIRE / July 25, 2023 / The Power Play by The Market Herald has announced the release of new interviews with Etruscus Resources, Filament Health and Lancaster Resources discussing their latest news. The Power Play by The Market Herald provides investors with a quick snapsho...
News, Short Squeeze, Breakout and More Instantly...
FILAMENT HEALTH CORP. Company Name:
FH:CC Stock Symbol:
AQNC Market:
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Canada NewsWire VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " ...
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Canada NewsWire Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada...
FILAMENT HEALTH ANNOUNCES WARRANT EXERCISE AND NOTE CONVERSION BY NEGEV CAPITAL AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES TO BENJAMIN LIGHTBURN, CHIEF EXECUTIVE OFFICER Canada NewsWire VANCOUVER, BC , June 3, 2024 /CNW/ - Filament Health Corp. (OTCQB:...